Assignee
RESVERLOGIX CORP
CA·11 granted patents·8 pending applications·107 citations·filing 2005–2021
Top patents by PatentIndex Score
19 records- 0197US8053440B2Compounds for the prevention and treatment of cardiovascular diseasesRESVERLOGIX CORP·Filed 2007·Granted Nov 8, 2011·53 cites·34 claims
- 0295US7846915B2Stilbenes and chalcones for the prevention and treatment of cardiovascular diseasesRESVERLOGIX CORP·Filed 2005·Granted Dec 7, 2010·33 cites·13 claims
- 0388US11407719B2Anti-inflammatory agentsRESVERLOGIX CORP·Filed 2020·Granted Aug 9, 2022·1 cites·6 claims
- 0487US9610251B2Pharmaceutical compositions for substituted quinazolinonesRESVERLOGIX CORP·Filed 2012·Granted Apr 4, 2017·12 cites·7 claims
- 0583US10532054B2Compounds for the prevention and treatment of cardiovascular diseasesRESVERLOGIX CORP·Filed 2017·Granted Jan 14, 2020·2 cites·34 claims
- 0681US10882828B2Anti-inflammatory agentsRESVERLOGIX CORP·Filed 2018·Granted Jan 5, 2021·1 cites·12 claims
- 0777US2021361656A1Compounds for the prevention and treatment of cardiovascular diseasesRESVERLOGIX CORP·Filed 2021·Application pending·0 cites
- 0873US10131640B2Anti-inflammatory agentsRESVERLOGIX CORP·Filed 2015·Granted Nov 20, 2018·1 cites·39 claims
- 0973US2020352946A1Compounds for the prevention and treatment of cardiovascular diseasesRESVERLOGIX CORP·Filed 2019·Application pending·0 cites
- 1071US10111885B2Compositions and therapeutic methods for the treatment of complement-associated diseasesRESVERLOGIX CORP·Filed 2016·Granted Oct 30, 2018·3 cites·14 claims
- 1168US10772894B2Compositions and therapeutic methods for the treatment of complement-associated diseasesRESVERLOGIX CORP·Filed 2018·Granted Sep 15, 2020·1 cites·6 claims
- 1258US2020129512A1Novel anti-inflammatory agentsRESVERLOGIX CORP·Filed 2019·Application pending·0 cites
- 1352US2017333419A1Novel anti-inflammatory agentsRESVERLOGIX CORP·Filed 2017·Application pending·0 cites
- 1449US2016206617A1Compositions and therapeutic methods for accelerated plaque regressionRESVERLOGIX CORP·Filed 2014·Application pending·0 cites
- 1546US10016426B2Pharmaceutical compositions for substituted quinazolinonesRESVERLOGIX CORP·Filed 2017·Granted Jul 10, 2018·0 cites·15 claims
- 1645US2023381178A1Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitorRESVERLOGIX CORP·Filed 2021·Application pending·0 cites
- 1745US2023398137A1Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitorRESVERLOGIX CORP·Filed 2021·Application pending·0 cites
- 1842US12551484B2Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitorRESVERLOGIX CORP·Filed 2020·Granted Feb 17, 2026·0 cites·22 claims
- 1941US2023241064A1Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitorRESVERLOGIX CORP·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when RESVERLOGIX CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →